Jim Cramer's Stock Recommendations: ONEOK vs. DexCom
Overview of Jim Cramer's Recommendations
On CNBC's 'Mad Money Lightning Round,' financial expert Jim Cramer made some crucial recommendations regarding stock investments on August 5.
ONEOK: A Strong Buy
Cramer revealed that ONEOK (NYSE: OKE) is a solid buy, characterizing the company as 'terrific.' Investors are encouraged to consider increasing their positions in this energy stock.
- ONEOK reported a quarterly GAAP EPS of $1.33, exceeding expectations.
- This strong performance underlines the company's potential for future growth.
A Cautionary Note on DexCom
In contrast, Cramer advised staying away from DexCom, indicating potential risks associated with this stock.
- Cramer’s hiring practices involve research and assessment.
- Investors should heed Cramer's insights to navigate market opportunities effectively.
Conclusion
Jim Cramer's analysis offers significant insights into potential investment choices, especially in the energy sector with ONEOK. However, caution is warranted with DexCom, emphasizing the need to stay informed and make wise investment decisions based on market trends.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.